CME Group Inc. (NASDAQ:CME) Shares Sold by IMS Capital Management

IMS Capital Management decreased its position in shares of CME Group Inc. (NASDAQ:CME) by 10.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,594 shares of the financial services provider’s stock after selling 519 shares during the quarter. IMS Capital Management’s holdings in CME Group were worth $959,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of CME. Salomon & Ludwin LLC acquired a new position in CME Group in the first quarter valued at approximately $28,000. Y.D. More Investments Ltd acquired a new position in CME Group in the second quarter valued at $36,000. McClarren Financial Advisors Inc. raised its holdings in shares of CME Group by 66.1% in the second quarter. McClarren Financial Advisors Inc. now owns 196 shares of the financial services provider’s stock valued at $39,000 after buying an additional 78 shares during the last quarter. Asset Dedication LLC raised its holdings in shares of CME Group by 515.2% in the second quarter. Asset Dedication LLC now owns 203 shares of the financial services provider’s stock valued at $40,000 after buying an additional 170 shares during the last quarter. Finally, Rise Advisors LLC acquired a new stake in shares of CME Group during the first quarter worth about $41,000. Hedge funds and other institutional investors own 87.75% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their target price on CME Group from $193.00 to $200.00 and gave the company a “hold” rating in a report on Thursday, August 15th. TD Cowen assumed coverage on shares of CME Group in a research note on Thursday, September 26th. They issued a “hold” rating and a $221.00 price objective on the stock. Piper Sandler restated an “overweight” rating and issued a $225.00 target price on shares of CME Group in a research note on Tuesday, August 20th. Barclays boosted their price target on shares of CME Group from $208.00 to $209.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 25th. Finally, Keefe, Bruyette & Woods raised their price objective on shares of CME Group from $212.00 to $213.00 and gave the company a “market perform” rating in a research report on Thursday, July 25th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $212.54.

Insider Buying and Selling

In other news, CFO Lynne Fitzpatrick sold 754 shares of the stock in a transaction on Sunday, September 15th. The stock was sold at an average price of $216.99, for a total value of $163,610.46. Following the completion of the transaction, the chief financial officer now owns 13,261 shares of the company’s stock, valued at $2,877,504.39. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, Director Bryan T. Durkin sold 7,593 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the completion of the transaction, the director now owns 55,607 shares of the company’s stock, valued at $11,932,706.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Lynne Fitzpatrick sold 754 shares of the firm’s stock in a transaction dated Sunday, September 15th. The shares were sold at an average price of $216.99, for a total transaction of $163,610.46. Following the transaction, the chief financial officer now owns 13,261 shares of the company’s stock, valued at approximately $2,877,504.39. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company’s stock.

CME Group Stock Performance

CME stock opened at $220.65 on Tuesday. The firm has a market cap of $79.45 billion, a P/E ratio of 25.10, a P/E/G ratio of 8.74 and a beta of 0.55. CME Group Inc. has a 12-month low of $190.70 and a 12-month high of $223.80. The stock’s 50 day simple moving average is $210.11 and its 200 day simple moving average is $207.42. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.10.

CME Group (NASDAQ:CME) last announced its quarterly earnings results on Wednesday, July 24th. The financial services provider reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.03. CME Group had a return on equity of 12.82% and a net margin of 56.98%. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter last year, the business posted $2.30 EPS. The business’s revenue was up 12.7% on a year-over-year basis. As a group, equities research analysts predict that CME Group Inc. will post 9.94 EPS for the current year.

CME Group Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 25th. Stockholders of record on Monday, September 9th were given a dividend of $1.15 per share. The ex-dividend date was Monday, September 9th. This represents a $4.60 annualized dividend and a dividend yield of 2.08%. CME Group’s dividend payout ratio is presently 52.33%.

CME Group Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.